Genelux Corporation Common Stock (GNLX)
Stock · NASDAQ · Health Care
$2.42as of 10/16/2026
Price chart
Active signals
GNLX Signal Track Record
How signals performed across all stocks →What GNLX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | -6.5% | 41% | October 7, 2026 |
| Bollinger Band Breakout | 16 | -6.2% | 38% | May 8, 2026 |
| Bollinger Band Breakdown | 10 | +4.1% | 60% | September 4, 2026 |
| 200-Day Moving Average TouchActive now | 3 | +14.0% | 67% | July 3, 2025 |
| Any 20-session window (baseline) | -4.0% | 42% |
Computed by MarketWall from daily closing prices since November 9, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discover…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 25
- Website
- genelux.com/
Fundamentals
- 1-day range
- $2.32$2.5
- Market cap
- $121.07M
- P/E (trailing)
- —
- P/E (forward)
- -3.09
- EPS (trailing)
- $-0.87
- Dividend yield
- —
- Beta
- 0.55
- Avg. volume
- 272.5K
How Genelux Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Genelux Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- GNLXGenelux Corporation Common Stock$2.42▼ 2.42%Market cap $121.07MP/E —$2.29$8.54
- PMNProMIS Neurosciences Inc. Common Shares (ON)$8.15▼ 6.32%Market cap $119.54MP/E —$6.27$27.4
- BGMBGM Group Ltd. Class A Ordinary Shares$8.65▲ 0.70%Market cap $118.62MP/E —$6.45$303
- TLSATiziana Life Sciences Ltd. Common Shares$1.05▲ 0.00%Market cap $123.99MP/E —$0.7615$2.2
- IFRXInflaRx N.V. Common Stock$1.32▼ 8.33%Market cap $124.34MP/E —$0.7984$2.95
- YARWYarrow Bioscience Inc. Common Stock$18.31▼ 8.45%Market cap $116.71MP/E —$18.16$44.28
- ANIXAnixa Biosciences Inc. Common Stock$2.67▼ 3.96%Market cap $116.70MP/E —$2.32$5.46
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| GNLX Genelux Corporation Common Stock | $121.07M | — | $2.42 | ▼ 2.42% | $2.29$8.54 |
| PMN ProMIS Neurosciences Inc. Common Shares (ON) | $119.54M | — | $8.15 | ▼ 6.32% | $6.27$27.4 |
| BGM BGM Group Ltd. Class A Ordinary Shares | $118.62M | — | $8.65 | ▲ 0.70% | $6.45$303 |
| TLSA Tiziana Life Sciences Ltd. Common Shares | $123.99M | — | $1.05 | ▲ 0.00% | $0.7615$2.2 |
| IFRX InflaRx N.V. Common Stock | $124.34M | — | $1.32 | ▼ 8.33% | $0.7984$2.95 |
| YARW Yarrow Bioscience Inc. Common Stock | $116.71M | — | $18.31 | ▼ 8.45% | $18.16$44.28 |
| ANIX Anixa Biosciences Inc. Common Stock | $116.70M | — | $2.67 | ▼ 3.96% | $2.32$5.46 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Joseph Cappello · August 31, 2026 · Sale10.3K @ $2.74
- Thomas Zindrick · August 31, 2026 · Sale34.5K @ $2.67
- Yong Yu · August 31, 2026 · Sale9.7K @ $2.75
- Joseph Cappello · August 4, 2026 · Sale653 @ $2.95
- Thomas Zindrick · August 4, 2026 · Sale3.0K @ $2.95
- Yong Yu · August 4, 2026 · Sale653 @ $2.94
- John W. Smither · July 1, 2026 · Sale12.0K @ $2.91
- Matthew Pulisic · June 16, 2026 · Grant278.9K
- Eric Groen · June 16, 2026 · Grant234.0K
- John Thomas · June 16, 2026 · Grant28.4K
- Mary Mirabelli · June 16, 2026 · Grant31.6K
- Mary Mirabelli · June 16, 2026 · Grant28.4K
- Yong Yu · June 16, 2026 · Grant119.3K
- John W. Smither · June 16, 2026 · Grant31.6K
- John W. Smither · June 16, 2026 · Grant28.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 9.04M
- Total value held
- $22.65M
- Institutional holders
- 68
- Unknown2.12M
- Unknown1.70M
- Unknown1.38M
- Unknown453.8K
- Unknown405.9K
- Unknown323.9K
- Unknown280.9K
- Unknown250.0K
- Unknown164.5K
- Unknown155.7K
See the full, filterable feed with live charts on the MarketWall dashboard.